menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Gene Therapy Breakthrough in DMD: Insights from the EMBARK Trial

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    The EMBARK study is a global phase 3 trial investigating the safety and efficacy of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD) in children aged 4 to 7. Explore the study’s key findings with this brief recap. 

Facebook Comments

Recommended
Details
Comments
  • Overview

    The EMBARK study is a global phase 3 trial investigating the safety and efficacy of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD) in children aged 4 to 7. Explore the study’s key findings with this brief recap. 

Facebook Comments

Schedule24 May 2024